AVBP Stock Earnings Estimates Increased by HC Wainwright

Key Points

• HC Wainwright raised its ArriVent BioPharma EPS estimates, projecting a Q3 2026 loss of $1.02 per share versus its prior $1.04 estimate and narrowing its FY2026 and FY2027 loss forecasts to $4.06 and $3.97 per share, respectively.
• HC Wainwright maintained a Buy rating but set a $27 price target, while other analysts have also lowered targets. The stock has a consensus “Moderate Buy” rating and a $27.44 average target.
• ArriVent remains unprofitable and recently missed quarterly expectations, reporting a $1.05-per-share loss versus the $0.99 consensus estimate. Shares opened at $16.73, well below their 12-month high of $35.83.

ArriVent BioPharma, Inc. (NASDAQ:AVBP - Free Report) - Equities research analysts at HC Wainwright lifted their Q3 2026 earnings per share (EPS) estimates for ArriVent BioPharma in a report released on Thursday, October 8th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($1.02) per share for the quarter, up from their prior forecast of ($1.04). HC Wainwright has a "Buy" rating and a $27.00 price target on the stock. The consensus estimate for ArriVent BioPharma's current full-year earnings is ($4.05) per share. HC Wainwright also issued estimates for ArriVent BioPharma's Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($4.06) EPS, Q1 2027 earnings at ($0.96) EPS, Q2 2027 earnings at ($0.98) EPS, Q3 2027 earnings at ($1.00) EPS, Q4 2027 earnings at ($1.02) EPS and FY2027 earnings at ($3.97) EPS.

ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.06).

AVBP has been the subject of a number of other research reports. BTIG Research dropped their target price on ArriVent BioPharma from $42.00 to $29.00 and set a "buy" rating for the company in a research report on Wednesday. Truist Financial reduced their price target on shares of ArriVent BioPharma from $45.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, October 6th. JonesTrading reduced their price target on shares of ArriVent BioPharma from $45.00 to $22.00 and set a "buy" rating on the stock in a research report on Wednesday, October 7th. Jefferies Financial Group set a $18.00 price target on shares of ArriVent BioPharma in a research note on Tuesday, October 6th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of ArriVent BioPharma in a report on Friday, July 17th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, ArriVent BioPharma currently has an average rating of "Moderate Buy" and a consensus target price of $27.44.

ArriVent BioPharma Stock Performance

Shares of ArriVent BioPharma stock opened at $16.73 on Monday. The firm has a market capitalization of $824.96 million, a PE ratio of -4.62 and a beta of 1.34. ArriVent BioPharma has a 12 month low of $11.36 and a 12 month high of $35.83. The business's 50-day moving average price is $28.76 and its 200-day moving average price is $29.31.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of AVBP. Quantbot Technologies LP purchased a new position in ArriVent BioPharma in the 2nd quarter worth approximately $59,000. Bank of New York Mellon Corp boosted its stake in shares of ArriVent BioPharma by 3.2% during the first quarter. Bank of New York Mellon Corp now owns 75,448 shares of the company's stock valued at $1,741,000 after purchasing an additional 2,337 shares during the period. Jupiter Topco LLC purchased a new stake in shares of ArriVent BioPharma during the second quarter valued at approximately $226,000. Arizona State Retirement System purchased a new stake in shares of ArriVent BioPharma during the second quarter valued at approximately $233,000. Finally, Glenmede Trust Co. NA bought a new position in shares of ArriVent BioPharma in the first quarter worth approximately $209,000. 9.48% of the stock is owned by institutional investors.

Key ArriVent BioPharma News

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $4.06 from a loss of $4.14 and improved its estimates for several upcoming quarters. The firm also increased its FY2027 forecast to a loss of $3.97 from $4.24, suggesting it expects ArriVent’s losses to be somewhat narrower than previously projected. HC Wainwright maintained its Buy rating. ArriVent BioPharma Stock Price Target Cut by HC Wainwright
• Neutral Sentiment: The revised forecasts still call for substantial losses, including estimated quarterly losses of approximately $0.96 to $1.02 per share through 2027. The changes primarily reflect updated expectations rather than a new clinical, regulatory or commercial catalyst.
• Negative Sentiment: HC Wainwright reduced its price target to $27, despite retaining its Buy rating. A target reduction can weigh on sentiment because it signals less upside than previously anticipated, even though the target remains above the current trading level. ArriVent BioPharma Stock Price Target Cut by HC Wainwright
• Negative Sentiment: Wall Street Zen separately lowered its rating on ArriVent BioPharma, adding to the cautious tone surrounding the stock. The specific revised rating and rationale were not provided in the available report. ArriVent BioPharma Stock Rating Lowered by Wall Street Zen

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with genetically defined cancers. The company seeks to identify promising therapies developed in other regions and advance them through clinical development and regulatory approval in the United States and other markets.

ArriVent's lead product candidate is furmonertinib, an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor designed to target specific EGFR mutations in non-small cell lung cancer, including EGFR exon 20 insertion mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.